ARWR β€” ARROWHEAD PHARMACEUTICALS IN

Ownership history in Slate Path Capital LP  Β·  9 quarters on record

This page tracks every 13F SEC filing in which Slate Path Capital LP reported a position in ARROWHEAD PHARMACEUTICALS IN (ARWR). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
2.66% (2025 Q3)
πŸ“Š Avg. % of fund
1.79%
πŸ“… First filed
2023 Q4
πŸ“… Last filed
2025 Q4
⏱ Quarters held
9

Position Intelligence

Slate Path Capital LP Γ— ARWR AI Analytics

πŸ“ˆ Slate Path Capital LP outperformed the S&P 500 by +77.2% annually on this ARWR position. Timing score: 0% (0/4 decisions correct). Average cost basis: $25.96. Maximum drawdown during holding period: –55.5%.

πŸ“ˆ Position Alpha vs SPY
+77.2%
annualised excess return

πŸ”₯ Exceptional β€” beat the S&P 500 by 77.2% per year on this position.
7 quarters analyzed

⏱️ Timing Score
0%

⚠️ Poor timing β€” buys often preceded drops, trims preceded rallies.
0 of 4 add/trim decisions correct

πŸ’° Entry Quality
$25.96
+155.7% vs current ($66.39)

Best entry: $18.80 (2024 Q4)  Β·  Worst: $28.60 (2024 Q1)

πŸ›‘οΈ Drawdown Resilience
–55.5%
max drawdown while held

πŸ’ͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.

πŸ’ͺ Fund Conviction
67%
buy-side decisions

4 adds Β· 2 trims. Bought during 2 of 4 down-price quarters. πŸ“ˆ More buys than sells across the holding period.

πŸ“‘ Position Trajectory
↑ Growing
last 4–5 quarters trend

πŸ“ˆ Slate Path Capital LP has been actively increasing its ARWR allocation β€” a bullish signal from insiders.
Currently 2.26% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    ARWR price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 9 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 2,523,500 -2,458,500 -49.3% 2.26% $167.5M $66.39
2025 Q3 REDUCED 4,982,000 -250,000 -4.8% 2.66% $171.8M $34.49
2025 Q2 UNCHANGED 5,232,000 β€” 0% 1.43% $82.7M $15.80
2025 Q1 UNCHANGED 5,232,000 β€” 0% 1.20% $66.7M $12.74
2024 Q4 ADDED 5,232,000 +347,000 +7.1% 1.78% $98.4M $18.80
2024 Q3 ADDED 4,885,000 +746,000 +18.0% 1.46% $94.6M $19.37
2024 Q2 UNCHANGED 4,139,000 β€” 0% 2.05% $107.6M $25.99
2024 Q1 ADDED 4,139,000 +2,810,000 +211.4% 2.35% $118.4M $28.60
2023 Q4 INITIATED 1,329,000 β€” β€” 0.90% $40.7M β€”

🏒 Other funds also holding ARWR

As of 2025 Q4 β€” sorted by position size

Western Financial Corp/CA 3Y 21.6% Avoro Capital Advisors LLC 3Y 7Y 6.93% Privium Fund Management B.V. 3Y 4.87% M28 Capital Management LP 3Y 3.25% WEALTH EFFECTS LLC 3Y 2.98% Siren, L.L.C. 2.97% Vestal Point Capital, LP 2.03% Exome Asset Management LLC 1.58% DEERFIELD MANAGEMENT COMPANY, L.P. 3Y 7Y 1.55% PLATINUM INVESTMENT MANAGEMENT LTD 3Y 7Y 1.37%
← Back to Slate Path Capital LP Holdings